

Kinoxis Therapeutics Pty Ltd (Kinoxis) is a private, Australian-based, late preclinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders.



KINOXIS
T H E R A P E U T I C S

Kinoxis' development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney. Kinoxis' compounds are protected by a comprehensive Intellectual Property portfolio, filed in all major jurisdictions.

The company is backed by Uniseed, Australia's longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.

THERAPEUTIC FOCUS

Substance Use Disorders

Increased prevalence drug abuse represents a considerable treatment challenge for health professionals. In 2018, fewer than 20% of the 21.2 million people in the USA needing treatment for a substance use disorder received any treatment¹. This is, at least in part, driven by the limited number of approved pharmaceutical treatments (none approved for some substance use disorders), their minimal efficacy, and in some cases poor safety and tolerability. Despite this, medication-assisted treatment remains the recommended first line therapy for many substance use disorders. There is thus considerable need for more effective treatments.

Opioid Use Disorder

In the first half of 2019, approximately 80% of all overdose deaths involved one or more opioids.² However, FDA approved pharmacological treatments are limited and underutilised. For example, fewer than 20% of people in the USA with OUD receive an OUD-specific treatment. Overcoming the severe opioid withdrawal syndrome that emerges soon after ceasing or reducing opioid use is the first major barrier to recovery.

Despite this, there is only one non-opioid treatment approved for treating opioid withdrawal symptoms, lofexidine, and it suffers from limited efficacy and safety issues. Kinoxis' KNX100 program aims to help tackle the opioid epidemic by providing a more effective, safer treatment for the mitigation of opioid withdrawal symptoms.

Social Dysfunction

Disrupted social behaviour is a major symptom of many disorders of the brain and mind, including autism spectrum disorder, social anxiety disorder, substance use disorders, schizophrenia, depression, and dementia. Social dysfunction also presents a barrier to treatment, with engagement with positive social support networks identified as a critical factor in recovery. Despite this, there are currently no approved pharmacological treatments specifically targeting social symptoms in psychiatric and neurological disorders. Kinoxis is discovering and developing therapeutics that specifically enhance social functioning by targeting pathways in the brain involved in social behaviour, with a major focus on the oxytocin receptor.

THE EXECUTIVE TEAM



Hugh Alsop
CEO



Cameron James
CFO & Company
Secretary



Michael Bowen
CSO




Tina Soulis
VP, Clinical Strategy
& Development



Sharon Hanegraaf
VP, Drug
Development

KINOXIS PIPELINE

CANDIDATE SELECTION



CONTACT US

MELBOURNE AUSTRALIA

INFO@KINOXIS THERAPEUTICS.COM

KINOXIS THERAPEUTICS.COM

/COMPANY/KINOXIS-THERAPEUTICS-PTY-LTD

@KINOXIS_TX




KNX100

Kinosis' lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms via a novel, undisclosed mechanism of action. IND-enabling toxicology and Good Manufacturing Practice (GMP) scale-up has been completed for KNX100 and Phase I clinical trials will commence in the second half of 2021. The company is also exploring other indications for its lead compound, KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.

OXYTOCIN RECEPTOR TARGETING COMPOUNDS

Kinosis' second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder), social anxiety disorder, dementia (including Alzheimer's disease), and schizophrenia.

KNX100 Evaluated in 25 Different Animal Behavioural Models



Potent, Dose Dependent Efficacy Signals

- Methamphetamine use disorder
- Cocaine use disorder
- Alcohol use disorder
- Opioid use disorder
- Nicotine use disorder
- Agitation & Aggression